ARCA Historical Balance Sheet
ABIO Stock | USD 3.54 0.15 4.42% |
Trend analysis of ARCA Biopharma balance sheet accounts such as Short Long Term Debt Total of 239.4 K, Other Current Liabilities of 533 K or Total Current Liabilities of 605.1 K provides information on ARCA Biopharma's total assets, liabilities, and equity, which is the actual value of ARCA Biopharma to its prevalent stockholders. By breaking down trends over time using ARCA Biopharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining ARCA Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ARCA Biopharma is a good buy for the upcoming year.
ARCA |
About ARCA Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of ARCA Biopharma at a specified time, usually calculated after every quarter, six months, or one year. ARCA Biopharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ARCA Biopharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ARCA currently owns. An asset can also be divided into two categories, current and non-current.
ARCA Biopharma Balance Sheet Chart
ARCA Biopharma Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how ARCA Biopharma uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, ARCA Biopharma's Common Stock Shares Outstanding is very stable compared to the past year. As of the 28th of May 2024, Capital Lease Obligations is likely to grow to about 255.2 K, while Total Assets are likely to drop about 34.9 M. Add Fundamental
Total Assets
Total assets refers to the total amount of ARCA Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ARCA Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most accounts from ARCA Biopharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ARCA Biopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.At this time, ARCA Biopharma's Common Stock Shares Outstanding is very stable compared to the past year. As of the 28th of May 2024, Capital Lease Obligations is likely to grow to about 255.2 K, while Total Assets are likely to drop about 34.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 383K | 280K | 252K | 239.4K | Total Assets | 54.9M | 43.1M | 37.9M | 34.9M |
ARCA Biopharma balance sheet Correlations
Click cells to compare fundamentals
ARCA Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ARCA Biopharma balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 8.5M | 50.4M | 54.9M | 43.1M | 37.9M | 34.9M | |
Other Current Liab | 508K | 1.7M | 2.4M | 798K | 561K | 533.0K | |
Total Current Liabilities | 926K | 3.5M | 3.5M | 1.1M | 637K | 605.2K | |
Total Stockholder Equity | 7.6M | 46.5M | 51.0M | 41.7M | 37.0M | 22.4M | |
Property Plant And Equipment Net | 32K | 449K | 485K | 368K | 257K | 244.2K | |
Net Debt | (8.3M) | (48.7M) | (53.0M) | (42.2M) | (37.2M) | (35.3M) | |
Retained Earnings | (144.4M) | (154.2M) | (173.5M) | (183.4M) | (188.7M) | (198.2M) | |
Accounts Payable | 418K | 1.8M | 1.1M | 334K | 362K | 343.9K | |
Cash | 8.4M | 49.1M | 53.4M | 42.4M | 37.4M | 23.0M | |
Non Current Assets Total | 56K | 461K | 503K | 386K | 269.0K | 255.5K | |
Cash And Short Term Investments | 8.4M | 49.1M | 53.4M | 42.4M | 37.4M | 34.6M | |
Common Stock Shares Outstanding | 1.3M | 4.7M | 13.9M | 14.4M | 14.4M | 15.1M | |
Liabilities And Stockholders Equity | 8.5M | 50.4M | 54.9M | 43.1M | 37.9M | 34.9M | |
Non Current Liabilities Total | 418K | 409K | 383K | 280K | 204.0K | 193.8K | |
Other Current Assets | 117K | 897K | 1.1M | 254K | 161K | 153.0K | |
Other Stockholder Equity | 152.0M | 200.7M | 224.5M | 225.1M | 225.7M | 200.1M | |
Total Liab | 926K | 3.9M | 3.9M | 1.4M | 841K | 799.0K | |
Property Plant And Equipment Gross | 32K | 449K | 680K | 572K | 469K | 445.6K | |
Total Current Assets | 8.5M | 50.0M | 54.4M | 42.7M | 37.6M | 29.0M | |
Property Plant Equipment | 10K | 449K | 485K | 368K | 331.2K | 314.6K | |
Net Tangible Assets | 7.6M | 46.5M | 51.0M | 41.7M | 47.9M | 24.1M | |
Retained Earnings Total Equity | (131.0M) | (138.9M) | (144.4M) | (154.2M) | (138.7M) | (145.7M) | |
Capital Surpluse | 141.3M | 145.0M | 152.0M | 200.7M | 230.8M | 136.2M | |
Net Invested Capital | 7.6M | 46.5M | 51.0M | 41.7M | 37.0M | 31.5M | |
Net Working Capital | 7.6M | 46.5M | 50.9M | 41.6M | 37.0M | 31.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for ARCA Stock analysis
When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Transaction History View history of all your transactions and understand their impact on performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.42) | Return On Assets (0.13) | Return On Equity (0.16) |
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.